New pill could let EPP patients enjoy the sun without pain
NCT ID NCT03520036
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a drug called MT-7117 in 102 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight. Participants took either a low dose, high dose, or placebo daily for 16 weeks. The goal was to see if the drug could increase the time they could stay in the sun without symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT-7117
What this could lead to
If it works, this could lead to a daily pill that lets people with EPP spend more time in sunlight without pain.
What could go wrong
This is a small, early-phase trial. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACTCA, A Member of the Alliance, Inc.
Los Angeles, California, 90036, United States
-
Ichan School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Metro Boston Clinical Partners, LLC
Brighton, Massachusetts, 02135, United States
-
Remington-Davis, Inc
Columbus, Ohio, 43215, United States
-
University of California at San Francisco
San Francisco, California, 94143, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
-
University of Texas Medical Branch Porphyria Center
Galveston, Texas, 77555, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States